The important thing is knowing exactly how to handle it
In a 2025 phase 3 trial, participants lost between 9% and 15% of body weight over 48 weeks, comparable to semaglutide, but with fewer adverse effects (Reuters, 2025)
For more information about how this may affect your plan, please contact your Summit ReSources care specialist
The solution usually involves adjusting caloric intake, increasing activity, or discussing a dose escalation with their prescriber, not changing injection timing
Supplementary Applications Updates submitted for Ursodeoxycholic Acid, Oxcarbazepine, Nintedanib Esylate, and Acalabrutinibindicating lifecycle management and label optimization
You're saving $1,000-$1,900+ while receiving the same quality medication and superior support